Alembic Pharmaceuticals Limited

BSE:533573 Stock Report

Market Cap: ₹203.3b

Alembic Pharmaceuticals Valuation

Is 533573 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 533573 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 533573 (₹1029.25) is trading above our estimate of fair value (₹849.54)

Significantly Below Fair Value: 533573 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 533573?

Other financial metrics that can be useful for relative valuation.

533573 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.3x
Enterprise Value/EBITDA21.6x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does 533573's PE Ratio compare to its peers?

The above table shows the PE ratio for 533573 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average82.8x
530019 Jubilant Pharmova
31.8x5.5%₹188.4b
CONCORDBIO Concord Biotech
59.4x26.9%₹194.8b
506820 AstraZeneca Pharma India
193.3xn/a₹185.3b
EMCURE Emcure Pharmaceuticals
46.9x25.3%₹265.8b
533573 Alembic Pharmaceuticals
31.4x21.5%₹203.3b

Price-To-Earnings vs Peers: 533573 is good value based on its Price-To-Earnings Ratio (31.4x) compared to the peer average (82.8x).


Price to Earnings Ratio vs Industry

How does 533573's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 533573 is good value based on its Price-To-Earnings Ratio (31.4x) compared to the Indian Pharmaceuticals industry average (37.1x).


Price to Earnings Ratio vs Fair Ratio

What is 533573's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

533573 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.4x
Fair PE Ratio42.1x

Price-To-Earnings vs Fair Ratio: 533573 is good value based on its Price-To-Earnings Ratio (31.4x) compared to the estimated Fair Price-To-Earnings Ratio (42.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 533573 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,018.90
₹1,133.83
+11.3%
11.6%₹1,411.00₹895.00n/a12
Nov ’25₹1,121.40
₹1,092.58
-2.6%
13.0%₹1,396.00₹837.00n/a12
Oct ’25₹1,190.45
₹1,092.17
-8.3%
13.0%₹1,396.00₹837.00n/a12
Sep ’25₹1,060.25
₹1,056.33
-0.4%
14.3%₹1,396.00₹837.00n/a12
Aug ’25₹1,215.60
₹985.08
-19.0%
9.9%₹1,229.00₹845.00n/a13
Jul ’25₹923.90
₹983.54
+6.5%
9.8%₹1,229.00₹845.00n/a13
Jun ’25₹923.00
₹980.31
+6.2%
10.1%₹1,229.00₹845.00n/a13
May ’25₹996.75
₹937.69
-5.9%
9.7%₹1,143.00₹770.00n/a13
Apr ’25₹1,004.85
₹901.08
-10.3%
7.3%₹1,023.00₹770.00n/a13
Mar ’25₹1,051.05
₹888.14
-15.5%
8.9%₹1,023.00₹720.00n/a14
Feb ’25₹956.40
₹769.67
-19.5%
13.0%₹915.00₹515.00n/a15
Jan ’25₹765.40
₹742.44
-3.0%
15.2%₹915.00₹515.00n/a16
Dec ’24₹751.10
₹742.44
-1.2%
15.2%₹915.00₹515.00n/a16
Nov ’24₹712.20
₹723.07
+1.5%
15.1%₹895.00₹515.00₹1,121.4015
Oct ’24₹783.90
₹715.33
-8.7%
14.9%₹895.00₹515.00₹1,190.4515
Sep ’24₹770.00
₹715.33
-7.1%
14.9%₹895.00₹515.00₹1,060.2515
Aug ’24₹775.20
₹598.20
-22.8%
9.0%₹704.00₹515.00₹1,215.6015
Jul ’24₹636.20
₹590.87
-7.1%
8.7%₹704.00₹515.00₹923.9015
Jun ’24₹548.05
₹586.94
+7.1%
8.7%₹704.00₹515.00₹923.0016
May ’24₹556.80
₹601.25
+8.0%
7.7%₹704.00₹540.00₹996.7516
Apr ’24₹495.95
₹603.44
+21.7%
7.3%₹704.00₹540.00₹1,004.8516
Mar ’24₹507.45
₹630.24
+24.2%
14.5%₹944.00₹550.00₹1,051.0517
Feb ’24₹540.00
₹674.63
+24.9%
14.1%₹944.00₹563.00₹956.4016
Jan ’24₹573.05
₹676.50
+18.1%
14.2%₹944.00₹563.00₹765.4016
Dec ’23₹593.65
₹682.75
+15.0%
13.4%₹944.00₹563.00₹751.1016
Nov ’23₹578.45
₹681.44
+17.8%
14.0%₹944.00₹538.00₹712.2016

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies